BACKGROUND: Insulin resistance (IR) is highly prevalent in chronic hemodialysis (CHD) patients and is associated with poor cardiovascular outcomes. Hyperinsulinemic euglycemic glucose clamp (HEGC) is the gold standard for measuring IR. The comparison of commonly-used indirect indices of IR to HEGC has not been adequately performed in this population. Furthermore, the validity of newly proposed adipokine-based IR indices has not been explored. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is an observational study performed in a single center, involving 12 prevalent CHD patients (50 ± 9 years old, 100% African American, 33% women, body mass index of 34.4 ± 7.6 kg/m(2)) who were studied three consecutive times. IR was assessed by HEGC (glucose-disposal rate [GDR]), homeostatic model assessment of IR (HOMA-IR), HOMA-IR corrected by adiponectin (HOMA-AD), leptin adiponectin ratio (LAR), QUICKI, and the McAuley's index at each time point. RESULTS: Eighty-three percent of the subjects displayed either glucose intolerance or overt insulin resistance by HEGC (GDR median, 5.71; interquartile range [IQR], 4.16, 6.81). LAR and HOMA-AD were the best correlates of IR measured by HEGC (r=-0.72, P<0.001, and -0.67, P<0.001), respectively. Fat percentage, interleukin-6, and adipokines (leptin, adiponectin, and resistin) were strongly associated with GDR. HEGC, LAR, and HOMA-AD had the best intraclass correlation coefficients. CONCLUSION: IR is common in CHD patients. Adipokine-based indices are the best correlates of IR measurements by HEGC. HOMA-IR and QUICKI are reasonable alternatives. Use of these indices may allow better detection of alterations in insulin sensitivity in CHD patients.
BACKGROUND:Insulin resistance (IR) is highly prevalent in chronic hemodialysis (CHD) patients and is associated with poor cardiovascular outcomes. Hyperinsulinemic euglycemic glucose clamp (HEGC) is the gold standard for measuring IR. The comparison of commonly-used indirect indices of IR to HEGC has not been adequately performed in this population. Furthermore, the validity of newly proposed adipokine-based IR indices has not been explored. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is an observational study performed in a single center, involving 12 prevalent CHD patients (50 ± 9 years old, 100% African American, 33% women, body mass index of 34.4 ± 7.6 kg/m(2)) who were studied three consecutive times. IR was assessed by HEGC (glucose-disposal rate [GDR]), homeostatic model assessment of IR (HOMA-IR), HOMA-IR corrected by adiponectin (HOMA-AD), leptin adiponectin ratio (LAR), QUICKI, and the McAuley's index at each time point. RESULTS: Eighty-three percent of the subjects displayed either glucose intolerance or overt insulin resistance by HEGC (GDR median, 5.71; interquartile range [IQR], 4.16, 6.81). LAR and HOMA-AD were the best correlates of IR measured by HEGC (r=-0.72, P<0.001, and -0.67, P<0.001), respectively. Fat percentage, interleukin-6, and adipokines (leptin, adiponectin, and resistin) were strongly associated with GDR. HEGC, LAR, and HOMA-AD had the best intraclass correlation coefficients. CONCLUSION: IR is common in CHD patients. Adipokine-based indices are the best correlates of IR measurements by HEGC. HOMA-IR and QUICKI are reasonable alternatives. Use of these indices may allow better detection of alterations in insulin sensitivity in CHD patients.
Authors: A Katz; S S Nambi; K Mather; A D Baron; D A Follmann; G Sullivan; M J Quon Journal: J Clin Endocrinol Metab Date: 2000-07 Impact factor: 5.958
Authors: Juan F Ascaso; Susana Pardo; José T Real; Rosario I Lorente; Antonia Priego; Rafael Carmena Journal: Diabetes Care Date: 2003-12 Impact factor: 19.112
Authors: Claus M Larsen; Mirjam Faulenbach; Allan Vaag; Aage Vølund; Jan A Ehses; Burkhardt Seifert; Thomas Mandrup-Poulsen; Marc Y Donath Journal: N Engl J Med Date: 2007-04-12 Impact factor: 91.245
Authors: Iram Ahmad; Leila R Zelnick; Nicole R Robinson; Adriana M Hung; Bryan Kestenbaum; Kristina M Utzschneider; Steven E Kahn; Ian H de Boer Journal: Am J Physiol Endocrinol Metab Date: 2017-01-10 Impact factor: 4.310
Authors: Hong Xu; Xiaoyan Huang; Johan Arnlöv; Tommy Cederholm; Peter Stenvinkel; Bengt Lindholm; Ulf Risérus; Juan Jesús Carrero Journal: Clin J Am Soc Nephrol Date: 2014-01-16 Impact factor: 8.237
Authors: Mary F Feitosa; Alexander P Reiner; Mary K Wojczynski; Mariaelisa Graff; Kari E North; Jeffrey J Carr; Ingrid B Borecki Journal: Atherosclerosis Date: 2013-01-25 Impact factor: 5.162
Authors: Kelli R King-Morris; Serpil Muge Deger; Adriana M Hung; Phyllis Ann Egbert; Charles D Ellis; Amy Graves; Ayumi Shintani; T Alp Ikizler Journal: Perit Dial Int Date: 2015-11-02 Impact factor: 1.756
Authors: Ana Paula Bernardo; Jose C Oliveira; Olivia Santos; Maria J Carvalho; Antonio Cabrita; Anabela Rodrigues Journal: Clin J Am Soc Nephrol Date: 2015-10-27 Impact factor: 8.237
Authors: Adriana M Hung; Mary B Sundell; Natalia E Plotnikova; Aihua Bian; Ayumi Shintani; Charles D Ellis; Edward D Siew; T Alp Ikizler Journal: J Ren Nutr Date: 2012-09-07 Impact factor: 3.655
Authors: Serpil M Deger; Mary B Sundell; Edward D Siew; Phyllis Egbert; Charles D Ellis; Feng Sha; T Alp Ikizler; Adriana M Hung Journal: J Ren Nutr Date: 2012-11-27 Impact factor: 3.655